L
Lyvgen Biopharma
Lyvgen Biopharma is a Healthcare Company
About Lyvgen Biopharma
Lyvgen Biopharma is a clinical-stage biopharmaceutical company established in 2016, with a strategic focus on developing novel immuno-oncology therapeutics. The company was founded by Dr. Jieyi Wang, who currently serves as Chairman and CEO. Dr. Wang possesses extensive experience in oncology and immunotherapy research, having spent 22 years at Abbott/AbbVie where he led research teams that advanced multiple antibody-drug candidates into clinical development. This deep industry background in innovative drug discovery directly informs Lyvgen's mission to create new treatment options for cancer patients.
The company's core technology is the proprietary xLinkAb™ platform, which engineers agonist antibodies designed to activate immune co-stimulatory receptors selectively within the tumor microenvironment. This platform aims to solve a critical challenge in immunotherapy: maximizing anti-tumor activity while minimizing systemic toxicities often associated with first-generation agonists. The xLinkAb™ technology achieves this by creating antibodies with engineered Fc regions that require cross-linking by the FcγRIIB receptor—a receptor enriched on immune cells within the tumor—to become fully active. This mechanism concentrates the therapeutic effect at the tumor site, potentially offering a wider therapeutic window.
Lyvgen's business model centers on the in-house research and clinical development of its pipeline assets, while also being open to out-licensing and collaboration opportunities. The company has successfully raised significant capital to fund its operations, including a $30 million Series B round in 2018 and a Series C round in 2021 led by prominent investors such as IDG Capital and 6 Dimensions Capital. Lyvgen operates globally with research and development centers in Shanghai, a CMC process development site in Suzhou, and clinical and business development teams in both China and the US.
The clinical pipeline features several promising candidates. LVGN6051 (exlinkibart) is a monoclonal antibody agonist targeting CD137 (4-1BB), which has shown a favorable safety profile and preliminary efficacy in Phase I and Ib/II trials, both as a monotherapy and in combination with other agents like anti-PD-1 antibodies. Another key asset, LVGN7409, is a CD40 agonist monoclonal antibody designed to convert immunologically "cold" tumors into "hot" ones, making them more responsive to checkpoint inhibitors. This candidate has also advanced into clinical trials, demonstrating a tolerable safety profile in early studies. Through these programs, Lyvgen is developing treatments for a range of solid tumors, including head and neck, lung, and gastrointestinal cancers.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Feb 2021 | $20M | $150M | IDG Capital · FTZ Fund Management · China Renaissance · Longmen Ventures | — |
| SERIES BOther financing | Jul 2018 | $30M | $120M | 6 Dimensions Capital · 5Y Capital · Winfair Global · Shanghai Runling Investment | — |
Growth signals
Latest recorded traffic for Lyvgen Biopharma is 210 monthly website visits, down 77.4% over the last three months. Lyvgen Biopharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Lyvgen Biopharma in the Pudong ecosystem
The Lyvgen Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
6 Dimensions Capital
5Y Capital- WGWinfair Global
- SIShanghai Runling Investment
Series B and later5 investors entered at this stage
IDG Capital- FMFTZ Fund Management
China Renaissance- LVLongmen Ventures
- CIChengwei Chuangban Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Lyvgen Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lyvgen Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









